Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort.

Nowak, Albina; Huynh-Do, Uyen; Krayenbuehl, Pierre-Alexandre; Beuschlein, Felix; Schiffmann, Raphael; Barbey, Frédéric (2019). Fabry disease genotype, phenotype, and migalastat amenability: Insights from a national cohort. Journal of inherited metabolic diseases, 43(2), pp. 326-333. Wiley 10.1002/jimd.12167

[img] Text
2019_Fabry amenability_jimd proof.pdf - Accepted Version
Restricted to registered users only until 1 October 2021.
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy

Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by α-galactosidase A (α-Gal A) deficiency. The progressive accumulation of globotriaosylceramide results in life-threatening complications, including renal, cardiac, and cerebrovascular diseases. The pharmacological chaperone migalastat was recently approved as an alternative to enzyme replacement therapy in patients with amenable mutations. In this article, we investigate the proportion of amenable mutations, related to phenotype, in a population of adult patients with FD in Switzerland. This study included 170 adult patients (n = 64 males) from 46 independent pedigrees with 39 different identified mutations over the last 59 years. Overall, 68% had the classic phenotype and 48% fulfilled the current amenability criteria. Migalastat was stopped in 2/11 (18%) patients: the only male classic patient, because of lack of efficacy based on lyso-Gb3 levels, and one patient with a benign variant. In males, the achieved enzyme activities in peripheral leucocytes under migalastat treatment differed from the activities in HEK-cells after incubation with migalastat (eg, 33% in PL vs 41% HEK-cells for p.F113L; 43% in leucocytes vs 36% in HEK-cells for p.N215S, 24-30% in leucocytes vs 96% in HEK-cells for S238N). In this national cohort, we found a relatively high proportion of patients with amenable GLA mutations, which, however, had heterogeneous extent of amenability: the higher the residual α-Gal A activity, the higher the chaperone effect. Further studies are required to investigate the long-term benefits of migalastat therapy depending on the achieved enzyme activities in different amenable mutations.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Nephrology and Hypertension

UniBE Contributor:

Huynh-Do, Uyen

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0141-8955

Publisher:

Wiley

Language:

English

Submitter:

Uyen Huynh-Do

Date Deposited:

05 May 2020 17:36

Last Modified:

05 May 2020 17:36

Publisher DOI:

10.1002/jimd.12167

PubMed ID:

31449323

Uncontrolled Keywords:

Fabry disease amenable mutation lyso-Gb3 migalastat phenotype α-Galactosidase activity

BORIS DOI:

10.7892/boris.143654

URI:

https://boris.unibe.ch/id/eprint/143654

Actions (login required)

Edit item Edit item
Provide Feedback